Chem. Senses 26: 91-93,
2001
© Oxford University Press 2001
Clinical Bitterness Masking Test for Phantogeusia
Department of Otorhinolaryngology, School of Medicine, Kanazawa University, 13-1 Takara-machi, Kanazawa 920-8641, Japan
Correspondence to be sent to: Tadashi Ishimaru, Department of Otorhinolaryngology, School of Medicine, Kanazawa University, 13-1 Takara-machi, Kanazawa 920-8641, Japan. e-mail: ishimar{at}orl.m.kanazawa-u.ac.jp
| Abstract |
|---|
|
|
|---|
It is difficult to determine the reason why a patient complains of a bitter taste when their mouth is empty. We examined a new diagnostic test using a bitterness masking substance. The bitterness masking substance, Benecoat BMI-60 (hereafter BMI-60), is a masking substance specific to the taste cells bitterness receptors. After patients gargled with BMI-60 solutions, the phantom sensation of bitterness was masked in some patients, but was not masked in others. Bitter substances in saliva seemed to be masked by BMI-60, but bitterness did not seem to be masked when the locus of the phantom sensation was within the peripheral nerve and/or the brain. The bitterness masking test is useful for diagnosis of the phantom sensation of bitter taste.
| Introduction |
|---|
|
|
|---|
It is difficult to determine the reason why a patient complains of a bitter taste when their mouth is empty. When no clear evidence is discovered, patients are almost always diagnosed as having psychogenetic symptoms. What is causing the phantom sensation of bitterness? Is there a bitter substance in the saliva or is it a disease of the sense of taste? To distinguish between the former and the latter, a bitterness masking test was examined.
| Materials and methods |
|---|
|
|
|---|
We examined ten subjects, two male and eight female, who complained of a bitter taste in their empty mouths. We called complaints about this phantom sensation of bitterness phantogeusia. The age of the subjects was 63.3 ± 9.4 (mean ± SD) years old. The trial began October 1996 and ended July 1999. The subjects gave their informed consent for participation in the study, and experiments followed the World Medical Association Declaration of Helsinki Recommendations guiding physicians in biomedical research involving human subjects. The subjects gargled with 100 ml of 0.5% Benecoat BMI-60 (hereafter BMI-60; KAO Corporation, Tokyo, Japan) with distilled water. BMI-60 contains four lipoproteinsphosphatidic acid, phosphatidylcholine, phosphatidylinositol and phosphatidylethanolamineand is a specific inhibitor for bitterness (Katsuragi and Kurihara, 1993
|
| Results |
|---|
|
|
|---|
The patients were divided into two groups. The first group was composed of the six patients whose phantom sensation of bitterness was masked by BMI-60. The second group was composed of the four patients whose phantom sensation of bitterness was not masked by BMI-60. We called the former and latter BMI-60 positive and negative, respectively. Details are given in Table 1.
The difference in concentration of zinc levels between BMI-60 positive (82.6 ± 11.4, mean ± SD) and negative (75.3 ± 13.3, mean ± SD) was not significant (Students t-test, P > 0.05).
The difference in electrogustometric thresholds of the chorda tympanic area of the tongue between BMI-60 positive (14.3 ± 11.4, mean ± SD) and negative (26.0 ± 13.2, mean ± SD) was not significant (Students t-test, P > 0.05). Also, in the glossopharyngeal area of the tongue, the difference between BMI-60 positive (18.3 ± 8.1, mean ± SD) and negative (19.0 ± 9.6, mean ± SD) was not significant (Students t-test, P > 0.05).
The paper filter disk measurement method (Tomita et al., 1986
) was performed on patient no. 4. The taste thresholds of sweetness (sucrose), saltiness (sodium chloride), sourness (tartaric acid) and bitterness (quinine hydrochloride) in the chorda tympanic area of the right and left sides of the tongue were 1, off the scale, 3 and 1, off the scale, 1, 4 respectively.
| Discussion |
|---|
|
|
|---|
Aloenin, a bitter substance which is contained in aloe juice, is excreted in the urine of the rat (Hirata et al., 1981
Patient no. 2 complained that the phantom sensation of bitterness occurred when pain was felt in her right leg. Although it could not be determined whether this was a psychological or central nervous phenomenon, it is difficult to explain the relationship between the leg pain and secretion of the bitter substance in the saliva when no bitter substance was in her mouth.
It was difficult to diagnose the reason for phantogeusia in three BMI-60-positive patientsnos 3, 7 and 9. It was difficult to obtain evidence showing what medicine for brain infarction causes phantogeusia. BMI-60 blocks the molecules of bitterness receptors stimulated not only by bitter substances, but also for other unknown reasons. Thus, it is thought that something is continuously stimulating the molecules of the bitterness receptors, but the stimulated site was within the bitterness receptors.
In patient no. 4, who had ageusia with anosmia, a central nervous origin was suspected.
In patient no. 5, with dysfunction of the chorda tympanic nerve, the phantom sensation of bitterness caused by the cholesteatoma was not masked by BMI-60. The phantom sensation of bitterness seemed to be produced by stimulation of the cholesteatoma on the chorda tympanic nerve. Therefore, in this case, the phantom sensation of bitterness occurred without any bitter substance present in the mouth.
Patient no. 8, with a fissured tongue, had bleeding from the tongue. If the bitter taste was the taste of blood, the phantom sensation of bitterness may be masked by BMI-60. In this case, the phantom sensation of bitterness disappeared after the bleeding stopped.
Diabetic neuropathy seems to cause dysgeusia (Vescovi et al., 1991
). Diabetes might have caused the phantom sensation of bitterness in patient no. 10. Because this phantom sensation is thought to be due to chorda tympanic neuropathy, BMI-60 might not mask the phantom sensation of bitterness.
If the bitterness receptor cells could not sense the stimulant, BMI-60 could not mask bitterness. Therefore, it is expected the BMI-60 maskable subjects have lower electrogustometric thresholds than the non-maskable subjects. But the relationship between bitter maskability of BMI-60 and the electrogustometric threshold was not significant. The bitterness receptor cells might be desensitized by continuous stimulation of the bitterness receptors. Continuous bitterness stimulation may produce not only peripheral, but also central desensitization. The increased threshold of bitterness of the paper filter disk method measurement in patient no. 4 supports our hypothesis.
The bitterness masking test aids the diagnosis and understanding of phantogeusia.
| Acknowledgments |
|---|
We would like to thank Dr Yosihisa Katsuragi (Kao Corp., Health Care Products Research Laboratories) for supplying BMI-60.
| References |
|---|
|
|
|---|
Hirata T., Sakano, S. and Suga, T. (1981) Biotransformation of aloenin, a bitter glucoside constituent of Aloe arborescens, by rats. Experientia, 37, 12521253.[Web of Science][Medline]
Katsuragi, Y. and Kurihara, K. (1993) Specific inhibitor for bitter taste. Nature, 365, 213214.[Web of Science][Medline]
Katsuragi, Y., Sugiwara, Y., Lee, C., Otsuji, K. and Kurihara, K. (1995) Selective inhibition of bitter taste of various drugs by lipoprotein. Pharmaceut. Res., 12, 658662.[Web of Science][Medline]
Katsuragi, Y., Yasumasu, T. and Kurihara, K. (1996) Lipoprotein that selectively inhibits taste nerve responses to bitter substances. Brain Res., 713, 240245.[Web of Science][Medline]
Tomita, H., Ikeda, M. and Okuda, Y. (1986) Basic and practice of clinical taste examinations. Auris Nasusu Larynx, 13(Suppl. 1), S1S15.
Vescovi, P., Frigeri, S., Caccioli, P., Macaluso, G.M. and Oppici, A. (1991) Dysgeusia in clinical practice. 2. Pathology. Dent Cadmos, 59, 6875.
Accepted September 1, 2000
![]()
CiteULike
Connotea
Del.icio.us What's this?
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||